What is the recommended dose of meclizine (Antivert) for pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Meclizine dosing for children should be individualized based on the child's weight, age, and specific condition, with a recommended dose of 12.5 mg/day for patients under 20 kg and 25 mg/day for patients over 20 kg, as supported by the most recent study 1. When considering meclizine for children, it is essential to prioritize their weight and age to determine the appropriate dose.

  • For children under 20 kg, a dose of 12.5 mg/day is recommended, while for those over 20 kg, a dose of 25 mg/day is suggested, as indicated in the study 1.
  • The study 1 also highlights the importance of evaluating the safety and pharmacokinetics of meclizine in children, which is crucial for determining the optimal dose.
  • Meclizine works by blocking histamine H1 receptors and affecting the vestibular system, which helps reduce the sensation of motion and dizziness, as noted in the study 2.
  • Parents should always consult a pediatrician before giving meclizine to children, as dosing should be individualized based on the child's specific condition, and alternative medications or non-pharmacological approaches may be more appropriate for younger children experiencing motion sickness or vertigo, as suggested by the study 3.
  • The most recent and highest quality study 1 provides the best evidence for meclizine dosing in children, and its findings should be prioritized when making treatment decisions.

References

Research

Severe motion sickness in infants and children.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.